Condition: Esophageal Squamous Cell Carcinoma · Sponsor: Daiichi Sankyo
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
This description comes directly from the study's public registry record.
Daiichi Sankyo Contact for Clinical Trial Information · 9089926400 · CTRinfo_us@daiichisankyo.com
Always discuss trial participation with your own doctor first.
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| Baptist Cancer Center | Memphis, Tennessee, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| John Peter Smith Hospital | Fort Worth, Texas, United States | Recruiting |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
| Institut Jules Bordet | Brussels, Belgium | Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Antwerp University Hospital | Edegem, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Anyang Cancer Hospital | Anyang, China | Recruiting |
| Beijing Cancer Hospital | Beijing, China | Recruiting |
+ 76 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06644781